TY - JOUR
T1 - Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities
AU - Oben, Bénedith
AU - Froyen, Guy
AU - Maclachlan, Kylee H.
AU - Leongamornlert, Daniel
AU - Abascal, Federico
AU - Zheng-Lin, Binbin
AU - Yellapantula, Venkata
AU - Derkach, Andriy
AU - Geerdens, Ellen
AU - Diamond, Benjamin T.
AU - Arijs, Ingrid
AU - Maes, Brigitte
AU - Vanhees, Kimberly
AU - Hultcrantz, Malin
AU - Manasanch, Elisabet E.
AU - Kazandjian, Dickran
AU - Lesokhin, Alexander
AU - Dogan, Ahmet
AU - Zhang, Yanming
AU - Mikulasova, Aneta
AU - Walker, Brian
AU - Morgan, Gareth
AU - Campbell, Peter J.
AU - Landgren, Ola
AU - Rummens, Jean Luc
AU - Bolli, Niccolò
AU - Maura, Francesco
N1 - Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12/1
Y1 - 2021/12/1
N2 - Multiple myeloma (MM) is consistently preceded by precursor conditions recognized clinically as monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SMM). We interrogate the whole genome sequence (WGS) profile of 18 MGUS and compare them with those from 14 SMMs and 80 MMs. We show that cases with a non-progressing, clinically stable myeloma precursor condition (n = 15) are characterized by later initiation in the patient’s life and by the absence of myeloma defining genomic events including: chromothripsis, templated insertions, mutations in driver genes, aneuploidy, and canonical APOBEC mutational activity. This data provides evidence that WGS can be used to recognize two biologically and clinically distinct myeloma precursor entities that are either progressive or stable.
AB - Multiple myeloma (MM) is consistently preceded by precursor conditions recognized clinically as monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SMM). We interrogate the whole genome sequence (WGS) profile of 18 MGUS and compare them with those from 14 SMMs and 80 MMs. We show that cases with a non-progressing, clinically stable myeloma precursor condition (n = 15) are characterized by later initiation in the patient’s life and by the absence of myeloma defining genomic events including: chromothripsis, templated insertions, mutations in driver genes, aneuploidy, and canonical APOBEC mutational activity. This data provides evidence that WGS can be used to recognize two biologically and clinically distinct myeloma precursor entities that are either progressive or stable.
UR - http://www.scopus.com/inward/record.url?scp=85103392478&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103392478&partnerID=8YFLogxK
U2 - 10.1038/s41467-021-22140-0
DO - 10.1038/s41467-021-22140-0
M3 - Article
C2 - 33767199
AN - SCOPUS:85103392478
SN - 2041-1723
VL - 12
JO - Nature communications
JF - Nature communications
IS - 1
M1 - 1861
ER -